PDCD1 and skin squamous cell carcinoma: A pivotal phase I and II study investigated cemiplimab, a human IgG4 monoclonal antibody for PD-1, in advanced cSCC patients and found overall response rates of 47–50% and meaningful durable response rates of 61–65% [67].